Gadodiamide interactions
Full monograph for GadodiamideCheck it against another medicine
Medicines
166 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amlodipine Besilate + Atenolol | Moderate | Synergy · Unknown | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral…2 documented mechanisms | 4 sources — open the full entry |
| Atenolol | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Atenolol + Chlorthalidone | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Betaxolol Hydrochloride | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Bimatoprost + Timolol | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Bisoprolol Fumarate | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Synergy · Unknown | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral…2 documented mechanisms | 4 sources — open the full entry |
| Bisoprolol Fumarate + Hydrochlorothiazide | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleate | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Brinzolamide + Timolol | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Carvedilol | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Dorzolamide + Timolol | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Esmolol Hydrochloride | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Labetalol Hydrochloride | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Latanoprost + Timolol | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Metoprolol Tartrate | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Nebivolol + Hydrochlorothiazide | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Nebivolol + Valsartan | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Nebivolol Hydrochloride | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Propranolol Hydrochloride | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Sotalol Hydrochloride | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Timolol Maleate | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
| Travoprost + Timolol Maleate | Moderate | Synergy | Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral… | 4 sources — open the full entry |
Conditions
Conditions in which Gadodiamide needs care, as documented in this source.
Kidney Diseases
MajorGadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury. GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes). Always estimate the glomerular filtration rate (GFR) through laboratory testing.
3 sources
- "Product Information. ProHance (gadoteridol)." Bracco Diagnostics Inc (2001):
- "Product Information. Omniscan (gadodiamide)." Novation (2004):
- "Product Information. Magnevist (gadopentetate dimeglumine)." Berlex Laboratories (2005):
Hypersensitivity
ModerateSevere and fatal hypersensitivity reactions including anaphylaxis have been observed with administration of gadolinium based contrast agents, including gadoteridol. Patients with a history of allergy, drug reactions or other hypersensitivity-like disorders should be closely observed during the procedure and for several hours after drug administration. If a reaction occurs, stop administering and immediately begin appropriate therapy including resuscitation.
1 source
- "Product Information. ProHance (gadoteridol)." Bracco Diagnostics Inc (2001):